Here are 1-3 brief analogies for NanoVibronix (NAOV):

• BD (Becton, Dickinson and Company) for ultrasound-based catheter infection prevention.
• GE Healthcare for therapeutic ultrasound, not diagnostic imaging.

• PainBlocker™: A disposable, self-powered, wearable ultrasound device designed for localized pain relief.
• UroShield™: An ultrasound device intended to prevent catheter-associated urinary tract infections (CAUTI) and biofilm formation in indwelling catheters.
• WoundShield™: An ultrasound device designed to promote healing of chronic wounds and prevent infection.

NanoVibronix (symbol: NAOV) primarily sells its medical devices, such as PainShield and UroShield, to other companies. These customers are predominantly distributors, and potentially large healthcare organizations or group purchasing organizations.

According to its latest SEC filings, NanoVibronix's top three customers accounted for approximately 73% of its total revenue for the year ended December 31, 2023. However, the specific names of these major customer companies are not publicly disclosed in their financial reports or other investor communications due to competitive and proprietary reasons. Therefore, it is not possible to list the names or symbols of these specific customer companies.

Doron Besser, M.D. Chief Executive Officer

Dr. Doron Besser was appointed as the Chief Executive Officer of NanoVibronix on June 4, 2025. He previously served as the CEO of ENvue Medical Holdings, LLC, which NanoVibronix acquired in February 2025.

Stephen R. Brown Chief Financial Officer

Stephen Brown has served as the Chief Financial Officer of NanoVibronix since October 5, 2020. He previously held the CFO position at the company from February 3, 2015, through April 30, 2019, and continued as a financial consultant before his reappointment.

Harold Jacob, M.D. Chief Medical Officer

Dr. Harold Jacob is a co-founder of NanoVibronix and has served as its Chief Medical Officer since March 1, 2014, and as a director since September 2003. He was also the company's Chief Executive Officer from September 2003 to March 1, 2014, and served as chairman of the board of directors during part of that time. Dr. Jacob has worked extensively in medical device development and is also the president of Medical Instrument Development Inc., which provides consulting services and patents its own medical devices. He has filed for several patents related to medical devices and surface acoustic wave treatments.

Rita Silberberg Executive Vice President of Finance, Chief Accounting Officer and Secretary

Rita Silberberg serves as the Executive Vice President of Finance, Chief Accounting Officer, and Secretary for NanoVibronix.

Lindsey Harrison Vice President of Sales

Lindsey Harrison has been with NanoVibronix since 2015, serving in various roles before becoming the Vice President of Sales. She has 13 years of experience in the medical industry.

NanoVibronix (NAOV) has several anticipated drivers for future revenue growth over the next two to three years, primarily centered on product innovation, market expansion, and strategic partnerships.

1. New Product Development and Launches: The company is focused on the continued development and launch of innovative products leveraging its Surface Acoustic Wave (SAW) technology. NanoVibronix has been working on "NextGen prototypes" and has introduced a training aid called "Oscar" to accelerate the adoption of ENvue. The merger with ENvue Medical Holdings LLC in February 2025 is also expected to expand NanoVibronix's product lines and operations.
2. Expansion of Distribution Networks and Market Penetration: NanoVibronix aims to increase revenue by expanding its distribution networks to reach a broader customer base and by pursuing strategic alliances with hospitals and healthcare providers. The company is focused on expanding its market reach both domestically and in Europe. Specific initiatives include renewed distribution agreements, such as with Dukehill Healthcare Pty Ltd in Australia, and penetrating the Veterans Health System and the workers' compensation market segments within the U.S.
3. Increased Adoption and Efficacy of Core Products: The continued traction and successful studies of NanoVibronix's existing non-invasive therapeutic devices, such as UroShield, PainShield, and WoundShield, are expected to drive growth. Specifically, UroShield has shown efficacy in reducing catheter-associated infections and offering healthcare resource cost savings, which could lead to broader adoption. The company is also seeking FDA approval for UroShield, which, if granted, could significantly boost its market presence in the United States.
4. Strategic Partnerships and Alliances: Collaborations with healthcare providers, private label partnerships, and other strategic alliances are key to accelerating product adoption and expanding market access. An example is the General Services Administration (GSA) grant awarded to NanoVibronix and its VA partner, Delta Medical, LLC, which is anticipated to speed up product adoption within Veterans Health facilities.

Share Repurchases

No information available regarding share repurchases made or authorized for future repurchases over the last 3-5 years. The buyback yield was reported as -630.56% in the last 12 months, indicating an increase in shares rather than repurchases.

Share Issuance

• NanoVibronix completed a registered direct offering on September 16, 2025, selling 291,204 shares of common stock at $7.01 per share, generating gross proceeds of $2.0 million, intended for general working capital and debt repayment.
• On July 18, 2025, NanoVibronix entered into a definitive agreement for a private placement of Series H Convertible Preferred Stock, with an initial closing yielding approximately $8 million in gross proceeds from the sale of 8,889 shares, and a second closing for approximately $2 million. The agreement also included a right for the investor to purchase up to an additional $44 million stated value of preferred stock over 36 months.
• In January 2025, the company entered into a securities exchange agreement to issue 41,498 shares of common stock, a warrant to purchase up to 158,562 shares, and a pre-funded warrant to purchase up to 178,132 shares, in exchange for a previously held warrant.

Inbound Investments

• The company received approximately $8 million in gross proceeds from the initial closing of a private placement of Series H Convertible Preferred Stock from an institutional investor on or about July 21, 2025, with an additional $2 million from a second closing. The investor also has the right to purchase up to an aggregate of $44 million of additional preferred stock.
• NanoVibronix secured $2.0 million in gross proceeds from a registered direct offering to a single institutional investor for 291,204 shares of common stock in September 2025.
• On February 14, 2025, NanoVibronix consummated a merger with Predecessor ENvue, resulting in the former ENvue equity holders owning 19.9% of NanoVibronix's common stock and 85.0% of the outstanding equity (assuming Series X Preferred Stock conversion) immediately after the merger.

Outbound Investments

No specific information available regarding outbound strategic investments made by NanoVibronix in other companies over the last 3-5 years.

Capital Expenditures

• Capital expenditures for NanoVibronix were reported as -$9,000 in the last 12 months.
• Capital expenditures were $0.01 million in 2024.